Compare Gilead Sciences, Inc. (GILD) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Lam Research Corporation — how do they compare? Gilead Sciences, Inc. trades at $151.27 (market cap $182.40B), while Lam Research Corporation trades at $319.75 (market cap $401.19B). The key difference: Lam Research Corporation is far larger — about 2.2× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Lam Research Corporation for 60 Days on average.
| GILD | LRCX | |
|---|---|---|
Market Cap | $182.40B | $401.19B |
Volume | 4,469,821 | 8,960,892 |
Sector | Health | Technology |
52-Week High | $155.80 | $433.33 |
52-Week Low | $116.74 | $131.37 |
Typical Hold Time | 111 Days | 60 Days |
Enterprise Value | $205.46B | $399.35B |
Dividend Yield | 2.23% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Lam Research (LRCX) trades at $329.51, down 1.31% on the day, amid strong fundamental performance with revenue growth to $18.44B in 2025 and net income of $5.36B. The stock shows bullish technical signals with moving averages supporting upward momentum, while RSI levels indicate mixed short-term sentiment. Recent earnings beats and a consensus analyst price target of $375.68 suggest potential upside, supported by AI-driven demand for semiconductor equipment.
Outlook remains positive with expanding profit margins and robust cash flow, though valuation multiples like P/E of 55.66 pose risks if growth slows. Key opportunities include AI infrastructure spending and operational efficiency, while risks involve semiconductor cycle volatility and competitive pressures. Institutional sentiment is strongly bullish with 78% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
